Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages
- Kerstin A. Effenberger1,2,
- Veronica K. Urabe1,2,
- Beth E. Prichard1,2,
- Arun K. Ghosh3,4 and
- Melissa S. Jurica1,2
- 1Department of Molecular Cell and Developmental Biology, University of California, Santa Cruz, California 95064, USA
- 2Center for Molecular Biology of RNA, University of California, Santa Cruz, California 95064, USA
- 3Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, USA
- 4Department of Medicinal Chemistry, Purdue University, West Lafayette, Indiana 47907, USA
- Corresponding author: mjurica{at}ucsc.edu
Abstract
The protein SF3B1 is a core component of the spliceosome, the large ribonucleoprotein complex responsible for pre-mRNA splicing. Interest in SF3B1 intensified when tumor exome sequencing revealed frequent specific SF3B1 mutations in a variety of neoplasia and when SF3B1 was identified as the target of three different cancer cell growth inhibitors. A better mechanistic understanding of SF3B1's role in splicing is required to capitalize on these discoveries. Using the inhibitor compounds, we probed SF3B1 function in the spliceosome in an in vitro splicing system. Formerly, the inhibitors were shown to block early steps of spliceosome assembly, consistent with a previously determined role of SF3B1 in intron recognition. We now report that SF3B1 inhibitors also interfere with later events in the spliceosome cycle, including exon ligation. These observations are consistent with a requirement for SF3B1 throughout the splicing process. Additional experiments aimed at understanding how three structurally distinct molecules produce nearly identical effects on splicing revealed that inactive analogs of each compound interchangeably compete with the active inhibitors to restore splicing. The competition indicates that all three types of compounds interact with the same site on SF3B1 and likely interfere with its function by the same mechanism, supporting a shared pharmacophore model. It also suggests that SF3B1 inhibition does not result from binding alone, but is consistent with a model in which the compounds affect a conformational change in the protein. Together, our studies reveal new mechanistic insight into SF3B1 as a principal player in the spliceosome and as a target of inhibitor compounds.
Keywords
Footnotes
-
Article published online ahead of print. Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.053108.115.
- Received June 29, 2015.
- Accepted November 24, 2015.
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.
